Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice

Anna Vilgelm, Zenglin Lian, Hong Wang, Stephen L. Beauparlant, Andres Klein-Szanto, Lora Hedrick Ellenson, Antonio Di Cristofano

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

PTEN is a tumor suppressor gene frequently mutated in human cancers. In vitro and in vivo studies have shown that PTEN can exert its tumor suppressive function through a variety of mechanisms, including regulation of cell death and cell proliferation. However, it is still unclear which of the many downstream pathways are critical in each different tissue, in vivo. Loss of PTEN is the earliest detectable genetic lesion in the estrogen-related type I (endometrioid) endometrial cancer. Pten+/- mice develop endometrial neoplastic lesions with full penetrance, thus providing a model system to dissect the genetic and biochemical events leading to the transition from normal to hyperplastic and neoplastic endometrial epithelium. Here, we show that loss of Pten in the mouse endometrium activates Akt and results in increased phosphorylation of estrogen receptor α (ERα) on Ser167. ERα phosphorylation results, in turn, in the activation of this nuclear receptor both in vivo and in vitro, even in the absence of ligand, and in its increased ability to activate the transcription of several of its target genes. Strikingly, reduction of endometrial ERα. levels and activity dramatically reduces the neoplastic effect of Pten loss in the endometrium, in contrast to complete estrogen depletion. Thus, we provide for the first time in vivo evidence supporting the hypothesis that loss of Pten and subsequent Akt activation result in the activation of ERα-dependent pathways that play a pivotal role in the neoplastic process.

Original languageEnglish (US)
Pages (from-to)3375-3380
Number of pages6
JournalCancer Research
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Estrogen Receptors
Phosphorylation
Endometrium
Estrogens
Neoplastic Processes
Critical Pathways
Penetrance
Endometrial Neoplasms
Cytoplasmic and Nuclear Receptors
Tumor Suppressor Genes
Molecular Biology
Neoplasms
Cell Death
Epithelium
Cell Proliferation
Ligands
Genes
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice. / Vilgelm, Anna; Lian, Zenglin; Wang, Hong; Beauparlant, Stephen L.; Klein-Szanto, Andres; Ellenson, Lora Hedrick; Di Cristofano, Antonio.

In: Cancer Research, Vol. 66, No. 7, 01.04.2006, p. 3375-3380.

Research output: Contribution to journalArticle

Vilgelm, Anna ; Lian, Zenglin ; Wang, Hong ; Beauparlant, Stephen L. ; Klein-Szanto, Andres ; Ellenson, Lora Hedrick ; Di Cristofano, Antonio. / Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice. In: Cancer Research. 2006 ; Vol. 66, No. 7. pp. 3375-3380.
@article{599db342079b4be7879a5c5ceda9dce0,
title = "Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice",
abstract = "PTEN is a tumor suppressor gene frequently mutated in human cancers. In vitro and in vivo studies have shown that PTEN can exert its tumor suppressive function through a variety of mechanisms, including regulation of cell death and cell proliferation. However, it is still unclear which of the many downstream pathways are critical in each different tissue, in vivo. Loss of PTEN is the earliest detectable genetic lesion in the estrogen-related type I (endometrioid) endometrial cancer. Pten+/- mice develop endometrial neoplastic lesions with full penetrance, thus providing a model system to dissect the genetic and biochemical events leading to the transition from normal to hyperplastic and neoplastic endometrial epithelium. Here, we show that loss of Pten in the mouse endometrium activates Akt and results in increased phosphorylation of estrogen receptor α (ERα) on Ser167. ERα phosphorylation results, in turn, in the activation of this nuclear receptor both in vivo and in vitro, even in the absence of ligand, and in its increased ability to activate the transcription of several of its target genes. Strikingly, reduction of endometrial ERα. levels and activity dramatically reduces the neoplastic effect of Pten loss in the endometrium, in contrast to complete estrogen depletion. Thus, we provide for the first time in vivo evidence supporting the hypothesis that loss of Pten and subsequent Akt activation result in the activation of ERα-dependent pathways that play a pivotal role in the neoplastic process.",
author = "Anna Vilgelm and Zenglin Lian and Hong Wang and Beauparlant, {Stephen L.} and Andres Klein-Szanto and Ellenson, {Lora Hedrick} and {Di Cristofano}, Antonio",
year = "2006",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-05-4019",
language = "English (US)",
volume = "66",
pages = "3375--3380",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice

AU - Vilgelm, Anna

AU - Lian, Zenglin

AU - Wang, Hong

AU - Beauparlant, Stephen L.

AU - Klein-Szanto, Andres

AU - Ellenson, Lora Hedrick

AU - Di Cristofano, Antonio

PY - 2006/4/1

Y1 - 2006/4/1

N2 - PTEN is a tumor suppressor gene frequently mutated in human cancers. In vitro and in vivo studies have shown that PTEN can exert its tumor suppressive function through a variety of mechanisms, including regulation of cell death and cell proliferation. However, it is still unclear which of the many downstream pathways are critical in each different tissue, in vivo. Loss of PTEN is the earliest detectable genetic lesion in the estrogen-related type I (endometrioid) endometrial cancer. Pten+/- mice develop endometrial neoplastic lesions with full penetrance, thus providing a model system to dissect the genetic and biochemical events leading to the transition from normal to hyperplastic and neoplastic endometrial epithelium. Here, we show that loss of Pten in the mouse endometrium activates Akt and results in increased phosphorylation of estrogen receptor α (ERα) on Ser167. ERα phosphorylation results, in turn, in the activation of this nuclear receptor both in vivo and in vitro, even in the absence of ligand, and in its increased ability to activate the transcription of several of its target genes. Strikingly, reduction of endometrial ERα. levels and activity dramatically reduces the neoplastic effect of Pten loss in the endometrium, in contrast to complete estrogen depletion. Thus, we provide for the first time in vivo evidence supporting the hypothesis that loss of Pten and subsequent Akt activation result in the activation of ERα-dependent pathways that play a pivotal role in the neoplastic process.

AB - PTEN is a tumor suppressor gene frequently mutated in human cancers. In vitro and in vivo studies have shown that PTEN can exert its tumor suppressive function through a variety of mechanisms, including regulation of cell death and cell proliferation. However, it is still unclear which of the many downstream pathways are critical in each different tissue, in vivo. Loss of PTEN is the earliest detectable genetic lesion in the estrogen-related type I (endometrioid) endometrial cancer. Pten+/- mice develop endometrial neoplastic lesions with full penetrance, thus providing a model system to dissect the genetic and biochemical events leading to the transition from normal to hyperplastic and neoplastic endometrial epithelium. Here, we show that loss of Pten in the mouse endometrium activates Akt and results in increased phosphorylation of estrogen receptor α (ERα) on Ser167. ERα phosphorylation results, in turn, in the activation of this nuclear receptor both in vivo and in vitro, even in the absence of ligand, and in its increased ability to activate the transcription of several of its target genes. Strikingly, reduction of endometrial ERα. levels and activity dramatically reduces the neoplastic effect of Pten loss in the endometrium, in contrast to complete estrogen depletion. Thus, we provide for the first time in vivo evidence supporting the hypothesis that loss of Pten and subsequent Akt activation result in the activation of ERα-dependent pathways that play a pivotal role in the neoplastic process.

UR - http://www.scopus.com/inward/record.url?scp=33645742737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645742737&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4019

DO - 10.1158/0008-5472.CAN-05-4019

M3 - Article

C2 - 16585156

AN - SCOPUS:33645742737

VL - 66

SP - 3375

EP - 3380

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -